When deleting a study in the Chinese population [23], the ERCC2 Lys751Gln polymorphism showed significant effects on the risk of glioma, but the significance was much less (Z = 2.10, P = 0.04, OR = 0.89, 95%CI: 0.79–0.99). This evidence concerns the gene ERCC2 and central nervous system cancer.